These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30184276)

  • 1. Fluconazole resistance is not a predictor of poor outcome in patients with cryptococcosis.
    Vena A; Muñoz P; Guinea J; Escribano P; Peláez T; Valerio M; Bonache F; Gago S; Álvarez-Uría A; Bouza E
    Mycoses; 2019 May; 62(5):441-449. PubMed ID: 30184276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species.
    Bongomin F; Oladele RO; Gago S; Moore CB; Richardson MD
    Mycoses; 2018 May; 61(5):290-297. PubMed ID: 29377368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreasing fluconazole susceptibility of clinical South African Cryptococcus neoformans isolates over a decade.
    Naicker SD; Mpembe RS; Maphanga TG; Zulu TG; Desanto D; Wadula J; Mvelase N; Maluleka C; Reddy K; Dawood H; Maloba M; Govender NP;
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008137. PubMed ID: 32231354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluconazole resistance in cryptococcal disease: emerging or intrinsic?
    Cheong JW; McCormack J
    Med Mycol; 2013 Apr; 51(3):261-9. PubMed ID: 22989195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.
    Nielsen K; Vedula P; Smith KD; Meya DB; Garvey EP; Hoekstra WJ; Schotzinger RJ; Boulware DR
    Med Mycol; 2017 Jun; 55(4):453-456. PubMed ID: 27664991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for
    Delma FZ; Al-Hatmi AMS; Buil JB; van der Lee H; Tehupeiory-Kooreman M; de Hoog GS; Meletiadis J; Verweij PE
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diversity and Antifungal Drug Susceptibility of Cryptococcus Isolates in Thailand.
    Worasilchai N; Tangwattanachuleeporn M; Meesilpavikkai K; Folba C; Kangogo M; Groß U; Weig M; Bader O; Chindamporn A
    Med Mycol; 2017 Aug; 55(6):680-685. PubMed ID: 27915307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection.
    Aller AI; Martin-Mazuelos E; Lozano F; Gomez-Mateos J; Steele-Moore L; Holloway WJ; Gutiérrez MJ; Recio FJ; Espinel-Ingroff A
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1544-8. PubMed ID: 10817706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
    Dannaoui E; Abdul M; Arpin M; Michel-Nguyen A; Piens MA; Favel A; Lortholary O; Dromer F;
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2464-70. PubMed ID: 16801427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to therapy in patients with cryptococcosis and AIDS: Association with in vitro susceptibility to fluconazole.
    Agudelo CA; Muñoz C; Ramírez A; Tobón AM; de Bedout Bact C; Cano LE; Restrepo A
    Rev Iberoam Micol; 2015; 32(4):214-20. PubMed ID: 25637338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro combination between antifungals and diphenyl diselenide against Cryptococcus species.
    Rossato L; Loreto ES; Venturini TP; de Azevedo MI; Al-Hatmi AMS; Santurio JM; Alves SH
    Mycoses; 2019 Jun; 62(6):508-512. PubMed ID: 30776159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole.
    Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T; Baró-Tomás T
    Med Mycol; 2005 Sep; 43(6):505-10. PubMed ID: 16320494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11.
    Yang ML; Uhrig J; Vu K; Singapuri A; Dennis M; Gelli A; Thompson GR
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1202-7. PubMed ID: 26643330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis.
    Wirth F; de Azevedo MI; Pilla C; Aquino VR; Neto GW; Goldani LZ
    Med Mycol; 2018 Apr; 56(3):257-262. PubMed ID: 28992308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Berberine Antifungal Activity in Fluconazole-Resistant Pathogenic Yeasts: Action Mechanism Evaluated by Flow Cytometry and Biofilm Growth Inhibition in Candida spp.
    da Silva AR; de Andrade Neto JB; da Silva CR; Campos Rde S; Costa Silva RA; Freitas DD; do Nascimento FB; de Andrade LN; Sampaio LS; Grangeiro TB; Magalhães HI; Cavalcanti BC; de Moraes MO; Nobre Júnior HV
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3551-7. PubMed ID: 27021328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MICs and minimum fungicidal concentrations of posaconazole, voriconazole and fluconazole for Cryptococcus neoformans and Cryptococcus gattii.
    Torres-Rodríguez JM; Alvarado-Ramírez E; Murciano F; Sellart M
    J Antimicrob Chemother; 2008 Jul; 62(1):205-6. PubMed ID: 18375969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.